These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11048560)

  • 21. Creative cost-effectiveness analysis of CAPRIE data- dust in our eyes.
    Eriksson P
    Am J Med; 2005 Feb; 118(2):199-200; author reply 200. PubMed ID: 15694910
    [No Abstract]   [Full Text] [Related]  

  • 22. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
    Schleinitz MD; Weiss JP; Owens DK
    Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS
    J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Patients With Contraindications to Anticoagulation.
    Saw J; Bennell MC; Singh SM; Wijeysundera HC
    Can J Cardiol; 2016 Nov; 32(11):1355.e9-1355.e14. PubMed ID: 27432692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2006; 24(7):709-26. PubMed ID: 16802846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial.
    Lamy A; Tong W; Gao P; Chrolavicius S; Gafni A; Yusuf S; Connolly SJ
    Can J Cardiol; 2012; 28(1):95-101. PubMed ID: 21983111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France.
    Marissal JP; Selke B
    Pharmacoeconomics; 2004; 22(10):661-70. PubMed ID: 15244491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
    Ramsey SD
    N Engl J Med; 2003 Feb; 348(6):560-3; author reply 560-3. PubMed ID: 12572583
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
    Akinlade BK
    N Engl J Med; 2003 Feb; 348(6):560-3; author reply 560-3. PubMed ID: 12571267
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
    Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
    J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
    Armstrong EC
    N Engl J Med; 2003 Feb; 348(6):560-3; author reply 560-3. PubMed ID: 12572582
    [No Abstract]   [Full Text] [Related]  

  • 33. Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs into account.
    Prescrire Int; 2000 Jun; 9(47):82-3. PubMed ID: 11010748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [An acetylsalicylic acid-dypiridamole combination (Asasantine) in the prevention of the recurrence of cerebrovascular accidents (a cost-effectiveness analysis)].
    Kurz X; Annemans L; Dresse A
    Rev Med Liege; 1998 May; 53(5):265-9. PubMed ID: 9689880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.
    Lee VW; Tsai RB; Chow IH; Yan BP; Kaya MG; Park JW; Lam YY
    BMC Cardiovasc Disord; 2016 Aug; 16(1):167. PubMed ID: 27581874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia.
    Mejía A; Senior JM; Ceballos M; Atehortúa S; Toro JM; Saldarriaga C; Mejía ME; Ramírez C
    Biomedica; 2015; 35(4):531-40. PubMed ID: 26844442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
    Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
    Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.
    Sullivan PW; Arant TW; Ellis SL; Ulrich H
    Pharmacoeconomics; 2006; 24(10):1021-33. PubMed ID: 17002484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenaous coronary intervention: a Spanish model-based cost effectiveness analysis.
    Davies A; Sculpher M; Barrett A; Huete T; Sacristán JA; Dilla T
    Farm Hosp; 2013; 37(4):307-16. PubMed ID: 24010692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antifibrinolytics may be cost saving among recent recipients of combined acetylsalicylic acid and clopidogrel who undergo coronary artery bypass graft surgery.
    Ray JG; Hamielec CM
    Can J Cardiol; 2004 Jun; 20(8):829-30. PubMed ID: 15229768
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.